Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
EF Hutton analyst Jason Kolbert initiates coverage on Humacyte (NASDAQ:HUMA) with a Buy rating and announces Price Target of...
Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.
- Results presented at the Department of Defense's Military Health System Research Symposium (MHSRS) - - In real-world mili...
Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.
Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.24) by...
Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.
